GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases.

Vilarrasa N, Pellitero S.

Open source

DOI
10.1016/j.medcli.2025.107184
Published
2025-09-27
Container
Med Clin (Barc)
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.medcli.2025.107184,
  title = {GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases.},
  author = {Vilarrasa N and  Pellitero S.},
  year = {2025},
  journal = {Med Clin (Barc)},
  doi = {10.1016/j.medcli.2025.107184},
  url = {https://doi.org/10.1016/j.medcli.2025.107184}
}

RIS

TY  - JOUR
TI  - GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases.
AU  - Vilarrasa N
AU  -  Pellitero S.
PY  - 2025
JO  - Med Clin (Barc)
DO  - 10.1016/j.medcli.2025.107184
UR  - https://doi.org/10.1016/j.medcli.2025.107184
ER  - 

APA

N, V., & S., P. (2025). GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases.. Med Clin (Barc). https://doi.org/10.1016/j.medcli.2025.107184

Source records